Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemia

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 4, 2005, Pages

  Sasse, Emma C ^a   Sasse, Andre D ^a   Brandalise, Sílvia R ^b   Clark, Otavio Augusto Camara ^c   Richards, Sue ^d  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b CENTRO INFANTIL BOLDRINI   (Brazil)

^c Scientific Solutions in Healthcare   (Brazil)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEVER; HUMAN; META ANALYSIS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CHILD; FEVER; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MACROPHAGE COLONY-STIMULATING FACTOR; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 32944468224     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004139.pub2     Document Type: Review

References (79)

1. Calderwood S, Romeyer F, Blanchette V, Chan H, Doyle J, Greenberg M, et al. Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: randomized placebo-controlled study in childhood acute lymphoblastic leukemia. American Journal of Hematology 1994;47(1):27-32.
2. Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Medical Pediatric Oncology 1999;32(5):331-5.
3. Dibenedetto SP, Ragusa R, Ippolito AM, Lo Nigro L, Di Cataldo A, D'Amico S, et al. Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. European Journal of Haematology 1995;55(2):93-6.
4. Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E, et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 2000;18(7):1517-24.
5. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. New England Journal of Medicine 1997;336(25):1781-7.
6. Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996;87(8):3143-50.
7. Chen SH, Liang DC, Liu HC. High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia. American Journal of Hematology 1998;58(1):20-3.
8. Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S, et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: A Children's Cancer Group Study. Journal of Clinical Oncology 2003;21:1612-7.
9. Laver J, Amylon M, Desai S, Link M, Schwenn M, Mahmoud H, et al. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. Journal of Clinical Oncology 1998;16(2):522-6.
10. Little MA, Morland B, Chisholm J, Hole A, Shankar A, Devine T, et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Medical Pediatric Oncology 2002;38(2):98-103.
11. Ohno R, Tomonaga M, Oshima T, Masaoka T, Asou N, Oh H, et al. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group. International Journal of Hematology 1993;58:73-81.
12. Saarinen-Pihkala UM, Lanning M, Perkkio M, Makipernaa A, Salmi TT, Hovi L, et al. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Medical Pediatric Oncology 2000;34(5):319-27.
13. Alexander SW, Pizzo PA. Current considerations in the management of fever and neutropenia. Current Clinical Topics of Infectious Diseases 1999;19:160-80.
14. Alvarado Ibarra ML, Borbolla Escoboza JR, Lopez-Hernandez MA, Gonzalez-Avante CM, FloresChapa JD, Trueba Christy E, et al. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF. Revista de Investigacion Clinica 1999;2:77-80.
15. Aquino VM, Tkaczewski I, Buchanan GR. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clinical Infectious Diseases 1997;25(1):74-8.
16. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998;92(12):4491-508.
17. Bash RO, Katz JA, Cash JV, Buchanan GR10. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74(1):189-96.
18. Benki I, Kovacs P, Szegedi I, Megyeri A, Kiss A, Balogh E, et al. Effect of myelopoieetic and pleiotropic cytokines on colony formation by bast cells of children with acute lymphoblastic leukemia. Naunyn-Schmiedeberg's Archives of Pharmacology 2001;363(5):499-508. [MEDLINE: 11383710]
19. Bennett CL, Stinson TJ, Lane D, Amylon M, Land VJ, Laver JH. Cost analysis of filgrastim for prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Medical Pediatric Oncology 2000;34:92-6.
20. Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH, et al. A comparison of efficacy of sargramostin (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Investigation 1998;6:366-73. [MEDLINE: 9679526]
21. Biesma B, De Vries EG, Willemse PH, Sluiter WJ, Postmus PE, Limburg PC, et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer 1990;26:932-36.
22. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factor to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database of Systematic Reviews 2008, (4). [CD: 003189.pub4; DOI: 10.1002/14651850]
23. Burdach SE, Muschenich M, Josephs W, Frisch J, Schulz G, Jurgens H, et al. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. Cancer 1995;76(3):510-6.
24. Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Medical Journal 1999;117(3):138-9.
25. Chanock SJ, Pizzo PA. Fever in the neutropenic host. Infectious Diseases Clinics of North America 1996;10(4):777-96.
26. Clark OAC, Lyman G, Castro AA, Clark LGO, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane Library 2005, Issue 1.
27. DerSimonian R, Laird N. Meta-analysis in clinical trial. Controlled Clinical Trials 1986;7(3):177-88.
28. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-91.
29. Egger M SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
30. Egger M SG, Altman D. Systematic Reviews in Health Care. 2nd Edition. BMJ Books, 2001.
31. Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Supportive Care in Cancer 2002;10(3):189-96.
32. Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP, et al. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. Journal of Clinical Oncology 1991;9(6):1022-8.
33. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute 2001;93:31-8.
34. Gattei V, Aldinucci D, Attadia V, Degan M, Alosi MS, De Iuliis A, et al. Human granulocyte-macrophage colony-stimulating factor supports the clonogenic growth of B-lineage acute lymphoblastic leukemias expressing myeloid antigens. Cytokines, Cellular & Molecular Therapy 1997;3(3):141-51. [MEDLINE: 9426972]
35. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991;338(8777):1223-6.
36. Griffin J. Hematopoietic Growth Factors. In: DeVitaJr VT HS, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. 6th Edition. Vol. 1, Lippincott Williams & Wilkins, 2001:2798-809.
37. Hasselblad VIC, Mccrory DC. Meta-analytic tools for medical decision making: a practical guide. Medical Decision Making 1995;15:81-96.
38. Higgins JPT, Thompsom SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
39. Higgins JPT, Thompson SG, Deekes JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
40. Inukai T, Sugita K, Iijima K, Goi K, Tezuka T, Kojika S, et al. Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. Leukemia 1998;12(3):382-9.
41. Kaushansky, K. Use of thrombopoietic growth factors in acute leukemia. Leukemia 2000;14(3):505-8.
42. Kritz A, Sepkowitz K, Weiss M, Telford P, Sogoloff H, Kempin S, et al. Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia. New England Journal of Medicine 1991;325(9):661-2.
43. Lechxin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
44. Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R, et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. British Journal of Cancer 1998;77(8):1294-9.
45. Lifton R, Bennett JM. Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy. Hematology and Oncology of Clinics of North America 1996;10(4):825-39.
46. Lok S, Foster DC. The structure, biology and potential therapeutic applications of recombinant thrombopoietin. Stem Cell 1994;12(6):586-98.
47. Madero L, Muonz A, Diaz de Heredia A, Martinez A, Badell I, Esquembre C, et al. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplantation 1995;15(3):349-51. [MEDLINE: 7541268]
48. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine 1994;121:492-501.
49. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute 1995;11(87):803-08.
50. McQuay HJ MR. Using numerical results from systematic reviews in clinical practice. Annals of Internal Medicine 1997;126(9):712-20.
51. Montaner JS, O'Shaughnessy MV, Schechter MT. Industry-sponsored clinical research: a double-edged sword. Lancet 2001;358(9296):1893-5. [DOI: 10.1016/S0140-6736(01)06891-X]
52. Nemunaitis JJ. RhGM-CSF in bone marrow transplantation: experience in pediatric patients. Medical Pediatric Oncology 1992;Supp 2:31-3.
53. Ohno R, Tomonaga M, Ohshima T, Masaoka T, Asou N, Oh H, et al. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group. International Journal of Hematology 1993;58(1-2):73-81.
54. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. Journal of Clinical Oncology 2000;18(20):3558-85.
55. Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, et al. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients. Haematologica 1999;11:1016-23.
56. Parsons SK. Oncology practice patterns in the use of hematopoietic growth factors. Current Opinion in Pediatrics 2000;12(1):10-7.
57. Petrilli AS, Bianchi A, Kusano E, Melaragno R, Naspitz C, Mendonca JS, et al. Fever and granulocytopenia in children with cancer: a study of 299 episodes with two treatment protocols in Brazil. Medical Pediatric Oncology 1993;21(5):356-61.
58. Petros WP. Colony-Stimulating Factors. In: Longo DL editor(s). Cancer Chemotherapy and Biotherapy - Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins Publishers, 2001.
59. Pierelli L, Perillo A, Ferrandina G, Salerno G, Rutella S, Fattorossi A, et al. The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. Transfusion 2001;12:1577-85.
60. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61(3):153-65.
61. Pizzo PA, Rubin M, Freifeld A, Walsh TJ. The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. Journal of Pediatrics 1991;119(5):679-94.
62. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New England Journal of Medicine 1993;328(18):1323-32.
63. Pizzo PA. Fever in immunocompromised patients. New England Journal of Medicine 1999;341(12):893-900.
64. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. New England Journal of Medicine 1997;336(25):1781-7.
65. Pui CH, Evans WE, Gilbert JR. Meeting report: International Childhood ALL Workshop: Memphis, TN, 3-4 December 1997. Leukemia 1998;12(8):1313-8.
66. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncology 2001;2(10):567-607.
67. Riikonen P, Saarinen UM, Makipernaa A, Hovi L, Komulainen A, Pihkala J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Diseases Journal 1994;13(3):197-202.
68. Riikonen P, Rahiala J, Salonvaara M, Perkkio M. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995;13(3):289-94.
69. Rosenman M, Madsen K, Hui S, Breitfeld PP. Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges. Journal of Pediatric Hematology and Oncology 2002;24(4):263-8.
70. Rubino C, Laplanche A, Patte C, Michon J. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma. Journal of the National Cancer Institute 1998;90(10):750-5.
71. Saarinen UM, Hovi L, Riikonen P, Pihkala J, Juvonen E. Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia. Medical Pediatric Oncology 1992;20(6):489-96.
72. Saarinen UM, Hovi L, Juvonen E, Riikonen P, Mottonen M, Makipernaa A. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children. Medical Pediatric Oncology 1996;26(6):380-6.
73. Schaison G, Eden OB, Henze G, Kamps WA, Locatelli F Ninane J, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. European Journal of Pediatrics 1998;157(12):955-66.
74. Trus MR, Bordeleau L, Pihl C, McGeer A, Prevost J, Minden MD, et al. Clinical manifestations associated with the aberrant expression of the soluble granulocyte-macrophage colony-stimulating factor receptor in patients presenting with haematological malignancies. British Journal of Haematology 2003;121(1):86-93.
75. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. Journal of Clinical Oncology 1995;13(4):1023-35.
76. Weaver CH, Schulman KA, Buckner CD. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy:a randomized comparison of filgrastim, sargramostim, or sequencial sargramostim and filgrastim. Bone Marrow Transplantation 2001;Suppl 2:S23-9.
77. Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Seminars in Hematology 1997;34(4):267-78.
78. Wexler LH, Weaver-McClure L, Steinberg SM, Jacobson J, Jarosinski P, Avila N, et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. Journal of Clinical Oncology 1996;14(3):901-10.
79. Yusuf S PR, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Programs Cardiovascular Disease 1985;27(5):335-71.